BioMarin develops therapies for rare genetic diseases, with a portfolio built around enzyme replacement, small molecules and gene therapy. Flagship products address conditions such as achondroplasia (Voxzogo), phenylketonuria and several lysosomal storage disorders. The company focuses on ultra-orphan indications where few or no alternatives exist, selling primarily to specialty clinics and rare-disease treatment centers worldwide.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 825.4 | — | 240.5 | — |
| Q3 2025 | 776.1 | — | -30.7 | — |
| Q4 2025 | 874.6 | — | -46.6 | — |
| Q1 2026 | 766.2 | — | 105.5 | — |
| Q2 2026 | 989.7 | 19.9% | 44.8 | -81.4% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Align Technology, Inc. (ALGN), JFrog Ltd. (FROG), Madrigal Pharmaceuticals, Inc. (MDGL), Amkor Technology, Inc. (AMKR), AGNC Investment Corp. (AGNC), The Ensign Group, Inc. (ENSG)